21 reports of this reaction
4.7% of all AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE reports
#2 most reported adverse reaction
BASAL CELL CARCINOMA is the #2 most commonly reported adverse reaction for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, manufactured by Kenvue Brands LLC. There are 21 FDA adverse event reports linking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE to BASAL CELL CARCINOMA. This represents approximately 4.7% of all 448 adverse event reports for this drug.
Patients taking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE who experience basal cell carcinoma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BASAL CELL CARCINOMA is moderately reported among AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE users, representing a notable but not dominant share of adverse events.
In addition to basal cell carcinoma, the following adverse reactions have been reported for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE:
The following drugs have also been linked to basal cell carcinoma in FDA adverse event reports:
BASAL CELL CARCINOMA has been reported as an adverse event in 21 FDA reports for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE. This does not prove causation, but indicates an association observed in post-market surveillance data.
BASAL CELL CARCINOMA accounts for approximately 4.7% of all adverse event reports for AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, making it one of the most commonly reported side effect.
If you experience basal cell carcinoma while taking AVOBENZONE, HOMOSALATE, OCTISALATE, AND OCTOCRYLENE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.